Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages

Key Points

• Analyst sentiment is cautious: Eleven firms have a consensus “Reduce” rating on Fresenius Medical Care, with five sells and six holds. The average 12-month price target is $23.57, modestly above the reported $22.36 opening price.
• Quarterly results exceeded expectations: The company reported adjusted earnings of $0.66 per share versus the $0.62 consensus estimate, while revenue reached $5.55 billion compared with expectations of $5.48 billion.
• Institutional ownership increased: Several hedge funds expanded their positions, although institutional investors collectively own only 8.37% of the company’s stock.

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) have been given a consensus recommendation of "Reduce" by the eleven ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $23.57.

FMS has been the topic of several research analyst reports. Truist Financial set a $25.00 price objective on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Citigroup reaffirmed a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. BNP Paribas Exane cut shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price target on the stock. in a research report on Tuesday, July 28th. Finally, Sanford C. Bernstein raised their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a research note on Thursday, August 6th.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.2%

Fresenius Medical Care AG & Co. KGaA stock opened at $22.36 on Friday. The company has a market capitalization of $12.01 billion, a PE ratio of 11.58, a price-to-earnings-growth ratio of 4.18 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The firm has a 50 day moving average price of $23.52 and a 200 day moving average price of $22.95.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The company had revenue of $5.55 billion for the quarter, compared to analysts' expectations of $5.48 billion. Research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FMS. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company's stock valued at $339,592,000 after acquiring an additional 299,986 shares in the last quarter. Moran Wealth Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company's stock worth $7,846,000 after purchasing an additional 83,311 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Fresenius Medical Care AG & Co. KGaA by 15.7% during the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company's stock worth $7,701,000 after purchasing an additional 46,428 shares during the period. Royal Bank of Canada increased its holdings in Fresenius Medical Care AG & Co. KGaA by 479.2% during the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock worth $4,893,000 after purchasing an additional 179,418 shares during the period. Finally, Assetmark Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 190.7% during the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company's stock worth $2,985,000 after purchasing an additional 86,798 shares during the period. Hedge funds and other institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.